Innovation and Technology Payment (ITP)
The Innovation and Technology Payment (ITP) builds on the Innovation and Technology Tariff (ITT) and aims to support the NHS in adopting innovation by removing financial or procurement barriers to uptake of innovative products or technologies.

Ideas (Publish, Detailed Submission)

Innovation 'Elevator Pitch':
A new type of surgical suture – stitch – that reduces the rate of surgery-linked infection (surgical site infection) such as MRSA, through the use of an antimicrobial triclosan coating.
Overview of Innovation:
Challenge/problem identified:

32% of hospital acquired infections are surgical site infections (SSI), most of which can be prevented.

Patients with an SSI are twice as likely to spend time in an intensive care unit and are five times more likely to be readmitted after discharge. They are also twice as likely to die.

50% of healthcare associated infections (HCAls) are associated with in-dwelling devices (Leaper D. et al., 2010). Sutures are often the overlooked implant.
The costs for an SSI are around €2,000-€4,000, while 9.8 days is the average extended length of stay (Leaper et al., 2004).



The solution:
 
Ethicon Plus Antibacterial Sutures are the only sutures available containing a coating of the antiseptic triclosan.

The triclosan used in Plus Sutures —IRGACARE® MP — is the purest form available and is shown in vitro to inhibit bacterial colonisation of the suture for seven days or more.

Since their approval, Plus Sutures have been clinically evaluated in multiple independent studies, published in peer reviewed journals including 25 randomised controlled trials (RCTs); 10 non RCTs; and eight meta-analyses.

All eight of the meta analyses published since 2012 conclude that there is a statistically significant reduction in SSIs when using Plus Sutures.

To find out more – click here.

 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Innovation and adoption
Benefit to NHS:
NICE 2008 Clinical Guidelines on Surgical Site Infection estimate the average cost of treating one SSI at £4,300.

PHE’s report “Surveillance of surgical site infections in NHS hospitals in England” states that in Apr 2016 to Mar 2017, data on 139,691 procedures and 1,635 surgical site infections (SSIs) detected during the inpatient stay or on readmission following the initial operation were collected by 201 NHS hospitals and 8 independent sector NHS treatment centres for 17 surgical categories under surveillance.

Looking at cardiac procedures only in one large NHS hospital teaching trust, 830 procedures were carried out over a 12-month period with an average SSI rate of 6%. If this trust converted to Plus Sutures, the estimated efficiency savings generated would be around £116,670, applying a 30% relative risk reduction in SSI and assuming the cost to treat SSI as advised by NICE. Furthermore, 141 bed days associated to SSIs would also be released.

Preventing SSIs also offers significant patient benefit, including a reduction in their length of stay, the antibiotics needed for treatment and avoidance of disruption to their personal life.
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
The NHS Innovation and Technology Payment (ITP) programme went live on 1 April 2018. Four innovations will be fast-tracked into use through the programme, supported by the AHSN Network. One of these is Plus Sutures – selected for central funding by NHS England.
 
Plus® Antibacterial Sutures are the only commercially available sutures with antibacterial protection.
 
Coated VICRYL Plus, MONOCRYL Plus and PDS Plus Sutures offer:
  • Proven in vitro to inhibit bacterial colonization of the suture for 7 days or more -1,2,3
  • Reduces the risk of biofilm formation on the suture - 4,5
  • Effective against the most common organisms associated with SSIs
  • Prospectively planned meta-analyses of randomized clinical trials were performed on the use of suture containing triclosan to lower surgical site infection rates - 6,7
 To view the references and out Plus Sutures One Pager – click here.
Current and planned activity: 
The NHS Innovation and Technology Payment (ITP) programme went live on 1 April 2018 with the aim of removing barriers to the spread and adoption of innovative products or technologies and the need for multiple price negotiations.
 
Innovations are directly funded by NHS England and are available to NHS organisations from April 2018 for one year, after which the support will be reviewed.
 
We would like WMAHSN to help to raise awareness of the ITP programme and Plus Sutures to enable regional NHS to realise savings by preventing SSIs and realising the significant patient benefit Plus Sutures offer, including a reduction in their length of stay, the antibiotics needed for treatment and avoidance of disruption to their personal life.
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
1 year
Ease of scalability: 
Simple
Read more
Hide details
Chloe Symes 25/04/2018 - 09:25 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Compared to adhesive securement devices, SecurAcath provides continuous securement from catheter placement and never needs to be changed.
Overview of Innovation:
Challenge/problem identified:

Patients may experience several complications when peripherally inserted central catheters (PICC) are moved or dislodged at the insertion site. During weekly routine dressing changes, the adhesive dressing are removed, leaving the catheter unsecured and at risk of movement and migration, which can lead to these adverse patient impacts:
  • Interruptions or delays in therapy
  • Increased length of hospital stay or extended treatment plan
  • Increased readmissions to hospital
  • Repeat procedures
  • Damaged vessels from catheter movement, pistoning or recatheterisation
  • Medical adhesive related skin injury (MARSI)
  • Complications including catheter occlusion, phlebitis, thrombosis and infection. 
The cost of replacing an adhesive securement on a weekly basis is around £5. Replacement costs of catheters can range from £150 to £1,500. Additional costs to consider are extending treatments and complication management.



Solution:

Compared to adhesive securement devices, SecurAcath provides continuous securement from catheter placement and never needs to be changed.

The concept for SecurAcath came from an Interventional Radiologist at the University of Minnesota.  He encountered patients with catheter securement issues on a daily basis and identified unmet needs for a robust catheter securement device that could overcome the challenges that adhesive devices and sutures caused.

SecurAcath does not require sutures or adhesives. It secures at the insertion site using small, flexible securement feet placed in the subcutaneous tissue below the dermis. This allows for improved site cleaning, less catheter manipulation and eliminates risk of accidental dislodgement or migration during routine dressing changes. Because SecurAcath lasts the life of the line, this lowers the total cost of patient care by dramatically reducing the complications related to routine adhesive securement changes and sutures.

The SecurAcath app can be downloaded via the App or Android store and used for training and educational purposes.


 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Innovation and adoption
Benefit to NHS:
Modelling shows a savings of £9-95 per patient compared to the Statlock adhesive securement device. Cost savings result from shorter maintenance times and less need for device replacement when using SecurAcath. Annual savings across the NHS in England from using SecurAcath are estimated to be a minimum of £4.2 million based on data reviewed by the NICE Advisory Committee. NICE estimated that 128,000 patients were eligible for the SecurAcath each year in England.

NICE concluded that the case for adopting SecurAcath is supported by the evidence. Using SecurAcath avoids the need for securement device replacement and is associated with a low incidence of catheter- associated complications, such as migration, occlusion, phlebitis, thrombosis and infection.
SecurAcath:
  • Dramatically reduced catheter dislodgement
  • Decreased catheter movement
  • Improved efficiency
  • 360-degree site cleaning while secured
  • No needle sticks
To find out more view our SecurAcath brochure – click here.
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
The NHS Innovation and Technology Payment (ITP) programme went live on 1 April 2018. Four innovations will be fast-tracked into use through the programme, supported by the AHSN Network. One of these is SecurAcath – selected for central funding by NHS England.

SecurAcath® provides improved catheter securement for the life of the line.
  • Prevents therapy interruption
  • May improve vessel health and preservation
  • Lowers total cost of patient care
SecurAcath is the only Subcutaneous Engineered Stabilization Device (ESD) that Meets the 2016 Infusion Therapy Standards of Practice.

Decreased Catheter Movement
  • Catheter movement at the insertion site can introduce bacteria beneath the skin
  • Improved stability may promote healing at insertion site, which acts as a natural barrier to infection
  • May reduce phlebitis, thrombosis and infection
Improved Efficiency
  • One SecurAcath secures for the life of the line
  • Catheter remains secure during dressing changes
  • Saves time during routine dressing changes
Dressing change can be done 3–5 minutes faster
  • Allows easy catheter repositioning if catheter tip must be pulled back 360-Degree Site Cleaning While Secured
  • Excellent cleaning access around the entire insertion site
  • Catheter remains stable and secure during cleaning
  • Improved stability and cleaning may help reduce infections
No Needle Sticks
  • Eliminates costly suture needlestick risk
  • Average cost of needlestick injury is $825
  • There are over 92,000 suture needlestick injuries to healthcare workers in the U.S. each year
Current and planned activity: 
The NHS Innovation and Technology Payment (ITP) programme went live on 1 April 2018 with the aim of removing barriers to the spread and adoption of innovative products or technologies and the need for multiple price negotiations.
 
Innovations are directly funded by NHS England and are available to NHS organisations from April 2018 for one year, after which the support will be reviewed.
 
We would like WMAHSN to help to raise awareness of the ITP programme and SecurAcath to enable regional NHS to realise savings and improve patient outcomes.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
N/A
Ease of scalability: 
3
Read more
Hide details
Scott Baker 25/04/2018 - 08:49 Publish Login or Register to post comments
0
0
Votes
-99999

Recent Activities

Active Campaigns

Top Contributors

User#Rank
Chloe Symes1
Scott Baker2